PAVmedPAVM.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, PAVmed (PAVM.O) trades at a negative P/E (-0.93x, due to a recent net loss), P/B of 0.55x, P/S of 172.10x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 19th percentile over the trailing 10Y window (vs. 61st percentile over 3Y); P/S sits at the 72nd percentile over the trailing 10Y window (vs. 69th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 11th percentile within its industry and the 11th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. PAVmed operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: PAVM · PAVM
Want the full picture on whether PAVmed (PAVM.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -0.93 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 0.55 | ||||||
| P/S (TTM) | 172.10 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |